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Abstract
The mechanism of the beneficial effects of Panax quinquefolius (Xiyangshen, American ginseng) on
diabetes is yet to be elucidated. Recent studies show that Panax quinquefolius increases insulin
production and reduces the death of pancreatic beta cells. Mechanism studies indicate that Panax
quinquefolius improves cell's immuno-reactivity and mitochondrial function through various factors.
Clinical studies show that Panax quinquefolius improves postprandial glycemia in type 2 diabetic
patients. Further studies to identify the component(s) of Panax quinquefolius linked with pancreatic
islets/beta cells in vitro and in vivo are warranted for better understanding of the full effects of Panax
quinquefolius.
Background
Increasing steadily in case numbers, diabetes mellitus has
become a devastating illness with significant morbidity
and mortality around the globe [1,2]. There are three types
of diabetes, namely type 1, type 2 and gestational, with
type 2 being the most common one. Type 1 juvenile dia-
betes is caused by auto-immune disorders leading to
extensive destruction of the insulin-producing beta cells
in the islets of Langerhans in the pancreas [3]. While type
2 adult-onset diabetes is related to insulin resistance, its
cause remains poorly understood. All type 1 and some of
type 2 diabetic patients require daily insulin shots. Either
replacement of destroyed beta cells via islets or pancreas
transplant is sometimes necessary [4].
In China, ginseng root has been used for millennia as a
tonic to increase vitality [5,6]. With the recent significant
increase in the usage of herbal remedies in the United
States [7], attention has been focused on the two most
popular types of ginseng, namely Panax quinquefolius L.
(Xiyangshen, American ginseng) and Panax ginseng CA
Meyer (Renshen, Asian ginseng) [3,8,9]. According to Chi-
nese medicine theory, the two ginseng types possess dif-
ferent properties and display different effects. Panax
ginseng increases blood flow and decreases fatigue. Exper-
imental studies indicate that Panax ginseng alleviates oxi-
dative stress generated by diabetes through the inhibition
of lipid peroxidation [10]. On the other hand, Panax quin-
quefolius has anti-aging effects, aids digestion [8] and has
anti-hyperglycemic effects. Clinical research studies dem-
onstrate that Panax quinquefolius may improve psycholog-
ical conditions, immune function and conditions
associated with diabetes (Table 1). Overall, Panax quinque-
folius  appears to be well tolerated, although caution is
advised about concomitant use with some pharmaceuti-
cals such as warfarin, oral hypoglycemic agents, insulin
and phenelzine [11]. Historical treatment of diabetes with
Eastern medicine includes integration of ginseng root
extracts in tonic form into the diet. While Panax quinque-
folius has been shown to facilitate anti-hyperglycemia, it is
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important to investigate whether it improves pancreatic
beta cell activities and whether it intervenes in various fac-
tors that may cause beta cell dysfunction and death. This
review will describe and discuss a possible mechanism of
anti-hyperglycemic effects of Panax quinquefolius by mod-
ulating pancreatic beta cell activities.
Ginseng components
The main active components in ginseng responsible for
ginseng's medical value have been identified as glyco-
sides. Glycoside is a naturally occurring substance consist-
ing of a sugar and non-sugar moiety. Some glycosides
belong to a family of compounds named saponins which
produce froth under agitation by reducing water surface
tension. A group of saponins in ginseng have been named
ginsenosides and classified into subclasses as Ro, Ra, Rb,
Rc, Rd, Re, Rf, Rg and Rh. These ginsenosides can be dif-
ferentiated in thin layer chromatography (TLC) based on
their retention factor value, which is the distance that gin-
senosides travel up the TLC column [12]. Panax ginseng
can be distinguished from Panax quinquefolius by using
ginsenoside profiles because Panax ginseng contains ginse-
noside Rf which is absent in Panax quinquefolius [13]. The
anti-hyperglycemic effects of the total ginsenosides
extracted from Panax ginseng were studied in diabetic
C57BL/6J ob/ob mice. The results indicate that the total
ginsenoside extract has significant anti-hyperglycemic and
anti-obesity properties [3]. In the same animal model, it
was revealed that the anti-hyperglycemic effect of ginseno-
side Re was due to improved muscle metabolism and that
ginsenoside improved diabetes by alleviating inflamma-
tion through increasing C-reactive protein levels [14].
Rh2, another ginseng component, lowered plasma glu-
cose level in Streptozotocin (STZ)-diabetic rats in a dosage
dependent manner [15]. Recent studies support the
notion that ginsenosides target steroid hormone recep-
tors, which suggests that these ginseng components act as
natural steroids, offering a diverse range of pharmacolog-
ical activities [16].
Panax quinquefolius facilitates normalization of 
hyperglycemia
Panax quinquefolius lowers blood glucose in diabetic
patients [9], increases pancreatic beta cell insulin produc-
tion and secretion, and prevents beta cell apoptosis [17].
The results also show that the effects of Panax quinquefolius
in stimulating insulin production/secretion and anti-
apoptosis are dosage dependent, suggesting a biological
specificity of ginseng water extracts on beta cells. A high
dosage of Panax quinquefolius is probably required to
reverse IL-1 beta induced apoptosis. According to a clini-
cal study by Vuksan et al., Panax quinquefolius attenuated
postprandial glycemia in both type 2 diabetic and non-
diabetic patients. While no difference was found in post-
prandial glycemia between placebo and ginseng groups in
non-diabetic subjects when administered together with
glucose challenge, in subjects with type 2 diabetes signifi-
cant reductions were observed when ginseng was taken 40
minutes before the glucose challenge [8].
Mechanism of Panax quinquefolius for 
normalization of hyperglycemia
The mechanism for the beneficial effects of Panax quinque-
folius has not been fully elucidated. According to our find-
ings, Panax quinquefolius water extracts reversed an IL-1
beta induced increase of uncoupling protein-2 (UCP-2, a
mitochondrial protein which uncouples electron trans-
port from ATP production), decreased pro-apoptotic pro-
tein caspase-9 and increased the level of anti-apoptotic
protein Bcl-2. This indicates that the anti-apoptotic effects
of Panax quinquefolius may be achieved through regulating
mitochondrial UCP-2 and ATP levels, thereby influencing
insulin synthesis and apoptotic cascades in beta cells [17]
(Figure 1). While cell metabolism seems to be a critical
factor targeted by Panax quinquefolius, there are other
reports on additional factors targeted by ginseng such as
immuno-reactivity [18]. Some other reports indicate that
Rh2 lowers plasma glucose level induced by an increase of
beta-endorphin secretion in STZ-diabetic rats, which acti-
vates opioid mu-receptors. The activation of opioid mu-
receptors increases the expression of GLUT 4, which raises
muscle and adipose tissue sensitivity to glucose stimula-
tion, thereby promoting tissue absorption of glucose,
which leads to a reduction in blood glucose level [15].
Another study on STZ-diabetic rats demonstrated that gin-
senoside Re relieved oxidative stress in the kidney and
eyes, and reduced blood glucose, cholesterol and triglyc-
eride levels. These findings suggest that different compo-
Table 1: Effects of American ginseng vs. those of Asian ginseng
Panax quinquefolius L. (Xiyangshen, American ginseng) Panax ginseng CA Meyer (Renshen, Asian ginseng)
Anti-aging Increases blood flow
Anti-hyperglycemic Decreases fatigue
Aids digestion Stimulates the nervous system
Reduces stress Anti-inflammatory agent
Enhances memory Aids insomnia
Improves sexual function Anti-depressionChinese Medicine 2007, 2:11 http://www.cmjournal.org/content/2/1/11
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nents of ginseng may act together to achieve its overall
therapeutic effects [19]. Protopanaxatriol (PPT), one of
the ginsenoside metabolites, increases GLUT4 and
improves insulin resistance [20]. Wang et al. reported that
Panax quinquefolius exerted an anti-lipolytic effect on type
2 diabetic conditions through a signaling pathway differ-
ent from that of insulin, suggesting that Panax quinquefo-
lius not only affects pancreatic cells through increasing
insulin production and cell viability, but also through cre-
ating an anti-lipolytic effect and targeting glucose recep-
tors to counter hyperglycemia [21]. Not only has ginseng
root been found to have positive effects, but also ginseng
leaf and berry extracts have been found to have potent
anti-oxidant activities against free radicals that are exces-
sively produced in diabetic complications [22]. Indeed,
these findings are merely the tip of the iceberg in terms of
the information required for elucidating the mechanism
for  Panax quinquefolius to improve hyperglycemia and
treat diabetes.
Panax quinquefolius improves beta cell insulin production
The inability to produce adequate amounts of insulin is a
factor attributed to beta cell dysfunction. Possible causes
include a disorder in beta cells preventing the production
of insulin and the death of the insulin producing beta
cells. When water extract of Panax quinquefolius was
administered to IL-1 beta cultured dysfunctional pancre-
atic beta cells, insulin production was significantly
increased in dysfunctional beta cells [17]. Apart from
many other factors, lack of insulin production is primarily
due to deficiency of ATP generated by mitochondria
[12,23]. Panax quinquefolius appears to enhance ATP pro-
duction. An inverse correlation between the amount of
ATP and the level of UCP-2 reveals an effect of Panax quin-
quefolius  on beta cell function. UCP-2 down-regulates
insulin secretion by preventing ATP production [23-27].
UCP-2 belongs to a family of anion mitochondrial trans-
porters linked to negatively regulated metabolism. UCP-2
has been found to be involved in anti-hyperinsulinemia
after the detection of the gene in pancreatic beta cells [27].
Cells induced with IL-1 beta exhibit a much higher level
of UCP-2, indicating that a high level of UCP-2 is harmful
to the cell. Cells with a high level of UCP-2 tend to have
lower survival rates [28]. Panax quinquefolius significantly
reduces the level of UCP-2 and increases ATP in the mito-
chondrion. Panax quinquefolius's ability to regulate UCP-2
may explain how it increases beta cell function and viabil-
ity.
Panax quinquefolius protects beta cells from apoptosis
A gradual loss of beta cells due to apoptosis (i.e. pro-
grammed cell death) significantly hinders insulin produc-
tion and inhibits cell viability. During apoptosis, cells
shrink; chromatin condenses; DNA is cleaved into pieces
at internucleosomal regions [18]. The cell breaks down
into small pieces which are then absorbed by neighboring
cells without causing inflammation. A proactive way to
increase beta cell viability is to decrease apoptosis level in
order to retain the cell population and increase insulin
production. Apoptosis is mediated by many factors, one
of which is the Bcl-2 proto-oncogene [29]. Bcl-2 protects
the cell against apoptosis by preventing activation of the
caspase cascade. The caspase cascade involves transloca-
tion of cytochrome c from the mitochondrion to activate
caspase-9 and then caspase-3, initiating the proteolytic
cascade essential for apoptosis [30]. Previous studies sug-
gest that Panax quinquefolius regulates pancreatic beta cell
apoptosis through mediating the levels of Bcl-2 and
capase-9 [17]. In a study of Bcl-2 and caspase-9 levels in
response to Panax quinquefolius in damaged cells showed
that Panax quinquefolius significantly up-regulated the lev-
els of Bcl-2 and down-regulated levels of caspase-9 expres-
sion [17]. IL-1 beta treated cells without ginseng
treatment showed a one-fold higher expression of pro-
apoptotic factor caspase-9 than that of cells with ginseng
The active components of Panax quinquefolius activate the  cytochrome-c related Bcl-2 and inhibit UCP-2 Figure 1
The active components of Panax quinquefolius activate the 
cytochrome-c related Bcl-2 and inhibit UCP-2. The activation 
of cytochrome-c related Bcl-2 has negative effects on cas-
pase-9 triggered apoptotic cascade and then apoptosis. As 
UCP-2 induces apoptotic cascade and decreases ATP pro-
duction, the inhibition of UCP-2 has negative effects on apop-
tosis and positive effects on ATP production, thereby 
increasing insulin production and release.   : up-regulated. 
 : down-regulated. + : positive effects. - : negative effects. 
 : known actions.   : recently discovered actions.
 
 Chinese Medicine 2007, 2:11 http://www.cmjournal.org/content/2/1/11
Page 4 of 5
(page number not for citation purposes)
treatment [17]. Panax quinquefolius may activate the mito-
chondrial membrane protein Bcl-2 to prevent cell apopto-
sis. By regulating the UCP-2 level, Panax quinquefolius
increases ATP production, thereby increasing insulin pro-
duction, meanwhile it prevents apoptosis by reducing cas-
pase-9 activation and raising levels of Bcl-2 [17]. Further
research is thus warranted in analyzing all aspects of Panax
quinquefolius's role in benefiting pancreatic beta cells.
Uncertainties
Due to a lack of standardization in the herbal medicine
industry, it is not certain whether the beneficial effects on
hyperglycemia hold true for all Panax quinquefolius prod-
ucts. It is also not certain whether different ginseng species
would have the same effects on hyperglycemia. Sieven-
piper et al. discovered that Panax ginseng showed both null
and opposing effects on acute postprandial plasma glu-
cose and insulin, which did not coincide with the findings
with Panax quinquefolius [31]. Reproducible efficacy using
an acute postprandial clinical screening model is neces-
sary to standardize herbal products and to link herbal
composition with efficacy in treating diabetes [32]. Fur-
ther data are also required to confirm that Panax ginseng
has the same effects on humans as it does in animal mod-
els.
Conclusion
Panax quinquefolius increases cell insulin production and
cell viability through mediating mitochondrial proteins
and apoptosis factors. These findings confirm that Panax
quinquefolius  improves pancreatic islet functions. The
components of Panax quinquefolius that improve pancre-
atic beta cell function have not been identified. The pre-
cise actions of Panax quinquefolius components on other
human cells such as muscle cells and lipocytes under dia-
betes therapy are yet to be investigated.
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